Assuntos
Carboxipeptidase B2/sangue , Humanos , Indicadores e Reagentes , Cinética , Métodos , Análise EspectralAssuntos
Carboxipeptidase B2/biossíntese , Estradiol/análogos & derivados , Estradiol/farmacologia , Fibrinólise/efeitos dos fármacos , Receptores de Estrogênio/metabolismo , Moduladores Seletivos de Receptor Estrogênico/farmacologia , Feminino , Humanos , Estudos Multicêntricos como Assunto , Razão de Chances , Placebos , Pós-Menopausa , Risco , Fatores de Risco , Fatores de TempoRESUMO
In an in vitro clot lysis model in human plasma, carboxypeptidase U (CPU) is generated by thrombin following the coagulation and by plasmin at the later stage of clot lysis. CPU is able to slow down clot lysis by suppressing the cofactor activity of partially degraded fibrin in the plasminogen activation by tissue-type plasminogen activator (t-PA). Making use of thrombomodulin and a thrombin inhibitor, the generation of CPU during the in vitro clot lysis can be manipulated both in terms of magnitude and time course. The data obtained demonstrate that CPU affects the clot dissolution through a threshold-dependent mechanism: as long as the CPU activity remains above the threshold value, lysis is prevented from proceeding into the propagation phase. From the moment the CPU activity drops below this threshold value, the rate of lysis accelerates. This threshold value for CPU activity is dictated by the t-PA concentration: increasing the t-PA concentration increases the CPU threshold and vice versa. This implies that the effect of the CPU pathway will become more apparent at a lower fibrinolytic capacity. Our threshold-based hypothesis indicates that the time course of proCPU activation, the stability of CPU and the t-PA concentration all play a crucial role in determining the result of the in vitro clot lysis experiment. Furthermore, this hypothesis provides us with new insights into previously published data on the effects of CPU on in vitro clot lysis by high and low t-PA concentrations.
Assuntos
Carboxipeptidase B2/metabolismo , Hemólise/fisiologia , Humanos , Cinética , Modelos Biológicos , Nefelometria e Turbidimetria , Proteínas Recombinantes/metabolismo , Valores de Referência , Trombina/metabolismo , Trombomodulina/fisiologia , Ativador de Plasminogênio Tecidual/metabolismoRESUMO
To test the hypothesis that the direct thrombin inhibitor, melagatran is able to inhibit local pro-carboxypeptidase U (proCPU) activation that occurs during thrombolytic treatment, t-PA alone, or in combination with melagatran, was given to dogs with a coronary artery thrombosis. Blood samples from the great cardiac vein and aorta were collected at baseline, during thrombus formation, throughout the t-PA+/-melagatran infusion and during the patency period, for analysis of CPU activity using a novel assay. A higher CPU activity in venous compared to arterial blood (V-A difference) indicates CPU activation in coronary vessels. Efficacy was assessed by determination of time to lysis, duration of patency and blood flow during patency. Dogs (n = 26) were randomized to receive either 1) t-PA, 1 mg/kg as an intravenous 20-min infusion; 2) t-PA as in group 1, +melagatran bolus, 0.3 mg/kg, followed by a 3-h infusion (0.15 mg/kg per h); 3) sham-operated but no coronary thrombus, and administered t-PA as for Group 1. All groups had similar baseline characteristics. Significant increases in CPU activity were observed in Groups 1 and 2 during thrombus formation, with V-A differences of 5.5 and 4.5 U/L, respectively. No significant V-A difference was observed in the sham-operated group. CPU activity increased in Group 1 during the t-PA infusion (V-A difference 15.9 U/L), whereas the V-A difference in Group 2 decreased to 2.6 U/L following melagatran treatment. These results demonstrate that melagatran attenuates generation of CPU in the coronary circulation. The mechanism is probably indirect, via inhibition of thrombin-mediated activation of proCPU.
Assuntos
Carboxipeptidase B2/antagonistas & inibidores , Carboxipeptidase B2/fisiologia , Circulação Coronária/efeitos dos fármacos , Trombose Coronária/tratamento farmacológico , Precursores Enzimáticos/antagonistas & inibidores , Fibrinolíticos/farmacologia , Glicina/análogos & derivados , Glicina/farmacologia , Terapia Trombolítica , Ativador de Plasminogênio Tecidual/farmacologia , Animais , Aorta , Azetidinas , Benzilaminas , Carboxipeptidase B2/sangue , Trombose Coronária/sangue , Trombose Coronária/enzimologia , Cães , Ativação Enzimática/efeitos dos fármacos , Precursores Enzimáticos/sangue , Feminino , Masculino , Modelos Animais , Distribuição Aleatória , Trombina/antagonistas & inibidores , VeiasRESUMO
OBJECTIVE: To investigate the effects of short-term postmenopausal oral hormone administration on plasma levels of procarboxypeptidase U (proCPU, thrombin-activatable fibrinolysis inhibitor, EC 3.4.17.20), an inhibitor of fibrinolysis, in healthy early postmenopausal women. DESIGN: A prospective, randomized, placebo-controlled study. SETTING: Outpatient clinic of the Department of Obstetrics and Gynaecology. SUBJECTS: Seventy-seven healthy early postmenopausal women were screened of whom 65 were randomized. Analyses were based on 60 participants. INTERVENTIONS: The women received oral micronized oestradiol 2 mg either alone (E2 group, n=16), or sequentially combined with dydrogesterone 10 mg (E2 + D group, n=14) or trimegestone 0.5 mg (E2 + T, n=14), or placebo (n=16) for 12 weeks. MAIN OUTCOME MEASURE: ProCPU concentrations at baseline, and at 4 and 12 weeks of treatment. RESULTS: Four weeks of E2 + T was associated with a significant decrease in the fasting proCPU concentration, which was sustained after 12 weeks [t=0: 636 +/- 57 U L(-1) (mean +/- SD); t=4: 583 +/- 63UL-1; t=12: 589 +/- 48 U L(-1); ANCOVA versus placebo: P=0.011]. The percentage change from baseline versus placebo in this group was -8.4% [95% confidence interval (CI) -15.7 to -1.1] after 4 weeks and -5.9% (95% CI -11.7 to -0.1) after 12 weeks. There were no significant changes versus placebo in the E2 group nor in the E2 + D group. CONCLUSION: Short-term treatment with E2 + T, but not E2 alone or E2 + D, lowers proCPU concentration. These findings add to accumulating evidence suggesting that different progestagens added to oestrogen replacement may differentially affect the risk of arterial and venous disease.
Assuntos
Carboxipeptidase B2/sangue , Estradiol , Terapia de Reposição de Estrogênios , Promegestona , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/fisiologia , Promegestona/análogos & derivados , Estudos ProspectivosRESUMO
Carboxypeptidase U (EC 3.4.17.20, CPU, TAFIa) is a novel determinant of the fibrinolytic rate. It circulates as an inactive zymogen, procarboxypeptidase U, which becomes active during the process of coagulation. We developed a high throughput method on microtiter plates for the determination of the procarboxypeptidase U concentration in human plasma samples. Following activation of procarboxypeptidase U by thrombin-thrombomodulin, the resulting enzyme activity cleaves p-OH-Hip-Arg and the generated p-OH-hippuric acid is converted by hippuricase to p-hydroxybenzoic acid and glycine. Finally, oxidative coupling of p-hydroxybenzoic acid with 4-aminoantipyrine by NaIO4 forms the quinoneimine dye. The absorbance of the latter dye is determined at 506 nm in a microtiter plate reader. A mean value of 620 U/l was found, with a CV of 3.0% within-run and 4.3% between-run. The assay showed a good correlation with the activities observed using a HPLC assay as reference method (n = 25, r = 0.979). The presented method enables the routine analysis of large sample pools in clinical setting.
Assuntos
Carboxipeptidase B2/sangue , Adulto , Idoso , Amidoidrolases/metabolismo , Ativação Enzimática , Feminino , Fibrinólise , Hipuratos/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Trombina , TrombomodulinaRESUMO
In 1988, Hendricks et al. first reported on the presence of carboxypeptidase U (U refers to the unstable nature of the enzyme) in human serum. One decade later, the importance of carboxypeptidase U (CPU) in the regulation of fibrin clot dissolution is well documented. CPU circulates in plasma as an inactive zymogen, proCPU, that is converted to its active form during coagulation and fibrinolysis. CPU cleaves off C-terminal lysine residues exposed on fibrin partially degraded by the action of plasmin. Because these C-terminal lysine residues are important for upregulating the fibrinolytic rate, CPU thus slows down fibrinolysis.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Carboxipeptidases/sangue , Fibrinólise/efeitos dos fármacos , Animais , Carboxipeptidase B2 , Carboxipeptidases/fisiologia , Hemostasia/efeitos dos fármacos , HumanosRESUMO
The importance of carboxypeptidase U as a novel regulator of the fibrinolytic rate has attracted a lot of interest recently. In the present work, an ELISA was developed using polyclonal antibodies raised against recombinant proCPU, expressed in DON cells. The assay determines the antigen concentration of the zymogen of carboxypeptidase U, procarboxypeptidase U, in human citrated plasma or EDTA plasma. No interference is observed with plasma carboxypeptidase N. The assay is very reproducible (within-run: 4.6% CV, between-run: 6.8% CV). In a group of 479 healthy individuals the mean proCPU antigen concentration is 13.4 microg/ml (SD 2.5 microg/ml). A good correlation is found with the functional procarboxypeptidase U assay described earlier (r = 0.82, p < 0.0001) (Schatteman K, Goossens F, Scharpé S, Neels H, Hendriks D Clin Chem 1999: 45: 807-813). The significant correlation between the proCPU antigen concentration and the 50% clot lysis time stresses its importance as a player in fibrinolysis control.
Assuntos
Carboxipeptidases/imunologia , Adulto , Fatores Etários , Anticorpos , Especificidade de Anticorpos , Antígenos/sangue , Carboxipeptidase B2 , Carboxipeptidases/sangue , Carboxipeptidases/normas , Ensaio de Imunoadsorção Enzimática/métodos , Ensaio de Imunoadsorção Enzimática/normas , Feminino , Fibrinólise/efeitos dos fármacos , Terapia de Reposição Hormonal , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Fatores SexuaisRESUMO
The value of mouth protectors in the prevention of facial and dental injuries was investigated in seven different sports. 5300 sportsmen filled in a written questionnaire. The replies provided information on the number of facial and dental injuries that occur annually in the Netherlands. The use of mouth protectors was also recorded.
Assuntos
Traumatismos em Atletas/prevenção & controle , Traumatismos Faciais/prevenção & controle , Protetores Bucais/estatística & dados numéricos , Traumatismos Dentários/prevenção & controle , Traumatismos em Atletas/epidemiologia , Traumatismos Faciais/epidemiologia , Feminino , Humanos , Masculino , Países Baixos/epidemiologia , Inquéritos e Questionários , Traumatismos Dentários/epidemiologiaRESUMO
In many respects international sportsmen are trendsetters for the behaviour of recreational sportsmen. For this reason the attitude of international hockey players towards mouth protectors was studied. The possession and use of mouth protectors vary markedly between different countries. The incidence of dental-facial traumas among international field hockey players is high; 54% had sustained injuries necessitating a visit to a physician and/or a dentist. Of these victims 20% sustained serious dental damage at least once (women 16% and men 22%). Only 20% of the international players wear a mouth protector consistently during training and matches. Women use the apparatus almost twice as much as men. The main argument in rejecting a mouth protector is that it is not felt to be necessary.